Waratah Capital Advisors Ltd. decreased its position in shares of Danaher Co. (NYSE:DHR) by 11.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,993 shares of the conglomerate’s stock after selling 18,087 shares during the quarter. Danaher comprises 2.2% of Waratah Capital Advisors Ltd.’s holdings, making the stock its 14th largest holding. Waratah Capital Advisors Ltd.’s holdings in Danaher were worth $19,353,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Howe & Rusling Inc. increased its position in Danaher by 116.3% during the 3rd quarter. Howe & Rusling Inc. now owns 186 shares of the conglomerate’s stock valued at $27,000 after buying an additional 100 shares in the last quarter. Next Capital Management LLC bought a new position in shares of Danaher during the second quarter valued at $31,000. Litman Gregory Asset Management LLC purchased a new stake in shares of Danaher during the second quarter valued at $33,000. Altshuler Shaham Ltd boosted its position in shares of Danaher by 59.3% during the second quarter. Altshuler Shaham Ltd now owns 239 shares of the conglomerate’s stock valued at $34,000 after buying an additional 89 shares during the last quarter. Finally, Pinnacle Bank increased its holdings in Danaher by 52.3% in the 3rd quarter. Pinnacle Bank now owns 262 shares of the conglomerate’s stock worth $38,000 after buying an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 78.10% of the company’s stock.
A number of brokerages have weighed in on DHR. UBS Group boosted their target price on Danaher from $158.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday. Needham & Company LLC reduced their price target on shares of Danaher from $155.00 to $152.00 and set a “buy” rating for the company in a research note on Monday, October 28th. ValuEngine cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Wolfe Research set a $154.00 price objective on shares of Danaher and gave the company a “buy” rating in a report on Friday, October 25th. Finally, Credit Suisse Group restated an “outperform” rating and set a $151.00 price objective on shares of Danaher in a research report on Monday, October 14th. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $147.53.
Shares of DHR traded down $0.32 on Tuesday, reaching $145.37. The company’s stock had a trading volume of 98,049 shares, compared to its average volume of 4,462,645. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.43 and a quick ratio of 3.09. The stock has a market capitalization of $104.85 billion, a P/E ratio of 32.22, a PEG ratio of 2.45 and a beta of 0.92. The stock’s 50 day simple moving average is $139.41 and its two-hundred day simple moving average is $139.58. Danaher Co. has a 12-month low of $94.59 and a 12-month high of $147.33.
Danaher (NYSE:DHR) last announced its earnings results on Thursday, October 24th. The conglomerate reported $1.16 EPS for the quarter, beating the Zacks’ consensus estimate of $1.15 by $0.01. The business had revenue of $5.04 billion during the quarter, compared to analysts’ expectations of $5.02 billion. Danaher had a net margin of 12.13% and a return on equity of 11.42%. The firm’s revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.10 earnings per share. Analysts expect that Danaher Co. will post 4.76 earnings per share for the current year.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Further Reading: Why do company’s buyback their stock?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.